UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 271

Sortiert nach

One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial

International journal of radiation oncology, biology, physics, 2019-11, Vol.105 (4), p.752-759

2019

Volltextzugriff (PDF)

Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy

Journal of clinical oncology, 2016-10, Vol.34 (30), p.3648-3654

2016

Volltextzugriff (PDF)

Prediction of Chest Wall Toxicity From Lung Stereotactic Body Radiotherapy (SBRT)

International journal of radiation oncology, biology, physics, 2012-02, Vol.82 (2), p.974-980

2012

Volltextzugriff (PDF)

Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2019-04, Vol.103 (5), p.1077-1084

2019

Volltextzugriff (PDF)

Salvage Stereotactic Body Radiation Therapy (SBRT) for Local Failure After Primary Lung SBRT

International journal of radiation oncology, biology, physics, 2014-10, Vol.90 (2), p.402-406

2014

Volltextzugriff (PDF)

Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2018-02, Vol.100 (2), p.462-469

2018

Volltextzugriff (PDF)

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

The lancet oncology, 2022-02, Vol.23 (2), p.279-291

2022

Volltextzugriff (PDF)

Esophageal Dose Tolerance to Hypofractionated Stereotactic Body Radiation Therapy: Risk Factors for Late Toxicity

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.197-202

2014

Volltextzugriff (PDF)

A Histologic Basis for the Efficacy of SBRT to the lung

Journal of thoracic oncology, 2017-03, Vol.12 (3), p.510-519

2017

Volltextzugriff (PDF)

Stereotactic body radiotherapy for stage I non-small cell lung cancer

Cleveland Clinic journal of medicine, 2012-05, Vol.79 Electronic Suppl 1 (5 e-suppl 1), p.eS26-S31

Stephans, Kevin

2012

Volltextzugriff (PDF)

Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early-Stage Lung Cancer

International journal of radiation oncology, biology, physics, 2021-10, Vol.111 (2), p.436-442

2021

Volltextzugriff (PDF)

Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy

International journal of radiation oncology, biology, physics, 2015-06, Vol.92 (2), p.325-331

2015

Volltextzugriff (PDF)

Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer

International journal of radiation oncology, biology, physics, 2019-06, Vol.104 (2), p.325-333

2019

Volltextzugriff (PDF)

30 Gy or 34 Gy? Comparing 2 Single-Fraction SBRT Dose Schedules for Stage I Medically Inoperable Non-Small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.203-208

2014

Volltextzugriff (PDF)

Intriguing, but Not the Right Setting

International journal of radiation oncology, biology, physics, 2017-07, Vol.98 (3), p.495-495

2017

Volltextzugriff (PDF)

Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients

International journal of radiation oncology, biology, physics, 2021-07, Vol.110 (3), p.731-737

2021

Volltextzugriff (PDF)

Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features

Lung cancer (Amsterdam, Netherlands), 2019-09, Vol.135, p.1-9

2019

Volltextzugriff (PDF)

Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes

International journal of radiation oncology, biology, physics, 2016-07, Vol.95 (3), p.960-964

2016

Volltextzugriff (PDF)

Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done

Cancers, 2022-02, Vol.14 (3), p.790

2022

Volltextzugriff (PDF)

Dosimetric assessment of patient‐specific breath‐hold reproducibility on liver motion for SBRT planning

Journal of applied clinical medical physics, 2020-07, Vol.21 (7), p.77-83

2020

Volltextzugriff (PDF)

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial

International journal of radiation oncology, biology, physics, 2017-06, Vol.98 (2), p.409-418

2017

Volltextzugriff (PDF)

Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy

The Journal of urology, 2019-10, Vol.202 (4), p.710-716

2019

Volltextzugriff (PDF)

Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy—A Multi-Institutional Observational Study

International journal of radiation oncology, biology, physics, 2016-12, Vol.96 (5), p.1046-1053

2016

Volltextzugriff (PDF)

Validation of RTOG 0813 Proximal Bronchial Tree Constraints for Pulmonary Toxicity With Stereotactic Body Radiation Therapy for Central Non-small Cell Lung Cancer

International journal of radiation oncology, biology, physics, 2020-05, Vol.107 (1), p.72-78

2020

Volltextzugriff (PDF)

Cyclotron and linear accelerator generated scanning proton beams for lung cancer SBRT: Interplay effects and mitigations

Medical physics (Lancaster), 2024-06, Vol.51 (6), p.3985-3994

2024

Volltextzugriff (PDF)

1 – 25 von 271

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(232)
Mit Volltextzugriff
(238)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(161)
Life Sciences & Biomedicine
(150)
Humans
(112)
Male
(83)
Oncology
(77)
Aged
(65)
Middle Aged
(62)
Female
(58)
Radiology, Nuclear Medicine & Medical Imaging
(50)
Aged, 80 And Over
(35)
Patients
(34)
Adult
(32)
Treatment Outcome
(32)
Radiology
(30)
Radiotherapy
(29)
Hematology, Oncology And Palliative Medicine
(27)
Lung Neoplasms - Pathology
(27)
Retrospective Studies
(24)
Radiosurgery - Methods
(23)
Carcinoma, Non-Small-Cell Lung - Pathology
(22)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial

Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy

Prediction of Chest Wall Toxicity From Lung Stereotactic Body Radiotherapy (SBRT)

Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer

Salvage Stereotactic Body Radiation Therapy (SBRT) for Local Failure After Primary Lung SBRT

Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Esophageal Dose Tolerance to Hypofractionated Stereotactic Body Radiation Therapy: Risk Factors for Late Toxicity

A Histologic Basis for the Efficacy of SBRT to the lung

Stereotactic body radiotherapy for stage I non-small cell lung cancer

Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early-Stage Lung Cancer

Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy

Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer

30 Gy or 34 Gy? Comparing 2 Single-Fraction SBRT Dose Schedules for Stage I Medically Inoperable Non-Small Cell Lung Cancer

Intriguing, but Not the Right Setting

Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients

Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features

Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes

Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done

Dosimetric assessment of patient‐specific breath‐hold reproducibility on liver motion for SBRT planning

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial

Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy

Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy—A Multi-Institutional Observational Study

Validation of RTOG 0813 Proximal Bronchial Tree Constraints for Pulmonary Toxicity With Stereotactic Body Radiation Therapy for Central Non-small Cell Lung Cancer

Cyclotron and linear accelerator generated scanning proton beams for lung cancer SBRT: Interplay effects and mitigations

Suchergebnisse filtern